|
|
Clinical effect of Compound Danshen Dropping Pills combined with Tolvaptan in the treatment of patients with acute myocardial infarction and heart failure |
WU Xiaoqiu HUANG Bin LIANG Shiwei |
Department of Cardiology, Chongzuo People′s Hospital, Guangxi Zhuang Autonomous Region, Chongzuo 532200, China |
|
|
Abstract Objective To investigate the clinical effect of Compound Danshen Dropping Pills combined with Tolvaptan in the treatment of patients with acute myocardial infarction (AMI) complicated with heart failure and the effect on serum cardiac troponin I (cTnI), myoglobin (Myo) levels in patients. Methods A hundred patients with AMI and heart failure admitted to the Department of Cardiovascular Medicine of Chongzuo People′s Hospital from January 2019 to June 2021 were selected as subjects for retrospective analysis, and divided into control group (50 cases) and experimental group (50 cases) according to the different treatment methods. The control group applied the drug treatment of Toraputan alone, and the experimental group combined the Compound Danshen Dropping Pills based on the control group. The clinical efficacy, total incidence rate of adverse reactions (thirst, frequency of urine), remission duration of clinical symptoms (dyspnea, chest pain, lower limb edema), and serum cTnI levels, and serum Myo levels were compared between the two groups of patients. Results The total clinical effective rate of experimental group was higher than that of control group, and the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The relief time of dyspnea, chest pain and lower limb edema in the experimental group was shorter than that in the control group, and the difference was statistically significant (P<0.05). Before treatment, there were no significant differences in serum cTnI and Myo levels between the two groups (P>0.05). After treatment, the levels of serum cTnI and Myo in the two groups were lower than those before tretment, the differences were statistically significant (P<0.05). The levels of serum cTnI and Myo in experimental group were lower than those in control group after treatment, with statistical significances (P<0.05). Conclusion The application of Compound Danshen Drop Pills with Torvarutan for patients with AMI and heart failure can significantly improve their serum cTnI and Myo levels, while improving the clinical treatment effect and shortening the remission time of dyspnea, chest pain and lower limb edema.
|
|
|
|
|
[1] |
张志亮,吕风华.复方丹参滴丸联合托伐普坦治疗急性心肌梗死并发心力衰竭的临床研究[J].现代药物与临床,2020,35(2):234-238.
|
[2] |
孟天伟,常虹.复方丹参滴丸治疗急性心肌梗死作用机制的网络药理学研究[J].中国中医急症,2021,30(11):1897-1901,1928.
|
[3] |
韩自旺.复方丹参滴丸联合抗凝治疗对急性心肌梗死患者PCI术后心功能及miR-1表达的影响[J].首都食品与医药,2021,28(22):83-85.
|
[4] |
赵吉玲,彭漪,徐维芳,等.复方丹参滴丸联合人脐血间充质干细胞移植对急性心肌梗死小鼠作用机制研究[J].中国中西医结合杂志,2021,41(9):1093-1099.
|
[5] |
牛瑞刚.复方丹参滴丸联合瑞舒伐他汀对PCI术后老年急性心肌梗死病人心功能及炎性因子的影响[J].中西医结合心脑血管病杂志,2020,18(7):1110-1113.
|
[6] |
王若涛,吴敏校,王开宇.复方丹参滴丸对急性心肌梗死患者经皮冠状动脉介入治疗术后血清微小RNA-1表达的影响[J].中国中西医结合急救杂志,2019,26(3):303-306.
|
[7] |
芦伟,朱坤,郑玉水.比伐芦定联合复方丹参滴丸对急性心肌梗死冠脉介入后心功能与肾胺酶及Ang-2水平的影响[J].中国临床研究,2021,34(3):304-308.
|
[8] |
高晟玮,刘志超,王振兴,等.复方丹参滴丸联合西医常规治疗对急性心肌梗死患者PCI术后临床疗效系统评价[J].辽宁中医药大学学报,2021,23(2):111-117.
|
[9] |
陈宏,魏冬梅,于丽,等.复方丹参滴丸对老年急性心肌梗死患者PCI术后血清炎症因子及T细胞亚群的影响[J].中国老年学杂志,2018,38(11):2586-2588.
|
[10] |
许小进,张一炎,张苏洁,等.复方丹参滴丸联合瑞舒伐他汀对急性心肌梗死经皮冠状动脉介入术后左心室重构及心肌纤维化的影响[J].中国医药导报,2019,16(35):61-64,77.
|
[11] |
赵悦,王吉佳,马雪,等.探讨阿托伐他汀治疗急性ST段抬高型心肌梗死合并高血压的效果观察[J].糖尿病天地,2019,16(6):56.
|
[12] |
何榕,张鸥,刘元伟,等.持续血液透析心肌梗死患者植入皮下植入型心律转复除颤器一例[J].中华心血管病杂志,2018,46(8):651-652.
|
[13] |
夏月平,王倩,崔炜.托伐普坦治疗急性心肌梗死后心力衰竭致高钠血症一例[J].中华心力衰竭和心肌病杂志,2020,04(1):63-65.
|
[14] |
纪东华.托伐普坦治疗AMI合并心力衰竭的疗效及对患者血清hs-CRP、NT-proBNP表达的影响[J].医学信息,2019,32(16):127-128.
|
[15] |
张浩.托伐普坦对急性心肌梗死后心力衰竭合并低钠血症患者的疗效及安全性观察[J].家庭医药·就医选药,2020,14(12):29.
|
|
|
|